Germany to pay more for child medicines amid supply shortage

By AP News

Share:

The German government said Tuesday that it will allow health insurance companies to pay more for pediatric medications that are in short supply in the country

Germany Medicine Shortages

BERLIN (AP) — The German government said Tuesday that it will allow health insurance companies to pay more for pediatric medications that are in short supply in the country.

Germans have scrambled to find basic drugs such as painkillers in recent weeks amid delivery bottlenecks and higher-than-usual demand.

Health Minister Karl Lauterbach said insurers that form the backbone of the German public health system will be able to pay 50% more than the legally set price for patent-free medicines. If such drugs aren't available, they can fall back on more expensive branded drugs or make liquids preferred for pediatric use out of tablets.

Germany, where the prices insurers pay for generic drugs are capped, is a less attractive market for some pharmaceutical companies than neighboring nations such as the Netherlands.

Lauterbach said Germany would also try to tackle a shortage of antibiotics and cancer drugs by giving preference to suppliers that produce key ingredients within the European Union and requiring them to keep several months worth of stocks.

German authorities say the country has a critical shortage of more than 50 drugs, most of them generics. The problem is caused by slim margins for some medications, a concentration of suppliers in certain non-EU countries, heightened demand and quality control issues.

Share:

Author: AP News

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Originally published by Associated Press Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

Sign up for Investing Intel Newsletter